Several analysts have recently updated their ratings and price targets for AnaptysBio (NASDAQ: ANAB):
- 8/31/2026 – AnaptysBio had its “outperform” rating reaffirmed by Wolfe Research. They now have a $78.00 price target on the stock.
- 8/25/2026 – AnaptysBio had its price target lowered by TD Cowen from $75.00 to $70.00. They now have a “buy” rating on the stock.
- 8/25/2026 – AnaptysBio was downgraded by Scotiabank to “hold”. They now have a $70.00 price target on the stock.
- 8/24/2026 – AnaptysBio had its “buy” rating reaffirmed by HC Wainwright. They now have a $95.00 price target on the stock.
- 8/7/2026 – AnaptysBio had its “sell (e+)” rating reaffirmed by Weiss Ratings.
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Read More
- Five stocks we like better than AnaptysBio
- AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone Opportunity
- MongoDB’s Spending Fears Collide With a Much Stronger Growth Story
- With the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?
- Could IonQ Become More Than a Quantum Computing Company?
Receive News & Ratings for AnaptysBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc and related companies with MarketBeat.com's FREE daily email newsletter.
